Name: 肝細胞癌における全身および局所免疫応答のマスサイトメトリー解析 (動画) | JoVE Journal
Uploaded: 2025-04-25T13:00:00.000+00:00
Duration: 8 min 25 s
Description: 学ぶマスサイトメトリーによる肝細胞癌における単一細胞レベルの免疫プロファイリング手法。14種類の免疫細胞サブセットを同定し、腫瘍免疫相互作用の理解と個別化治療への応用を可能にする。

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

<ol><li>Zhang, C. H., Cheng, Y., Zhang, S., Fan, J., Gao, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Changing+epidemiology+of+hepatocellular+carcinoma+in+Asia%5BTitle%5D)+AND+%22Liver+Int%22%5BJournal%5D)">Changing epidemiology of hepatocellular carcinoma in Asia.</a> Liver Int. 42 (9), 2029-2041 (2022).</li>
<li>Renne, S. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hepatocellular+carcinoma%3A+A+clinical+and+pathological+overview%5BTitle%5D)+AND+%22Pathologica%22%5BJournal%5D)">Hepatocellular carcinoma: A clinical and pathological overview.</a> Pathologica. 113 (3), 203-217 (2021).</li>
<li>Sayiner, M., Golabi, P., Younossi, Z. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Disease+burden+of+hepatocellular+carcinoma%3A+A+global+perspective%5BTitle%5D)+AND+%22Dig+Dis+Sci%22%5BJournal%5D)">Disease burden of hepatocellular carcinoma: A global perspective.</a> Dig Dis Sci. 64 (4), 910-917 (2019).</li>
<li>Zhang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Risk+factors+and+prevention+of+viral+hepatitis-related+hepatocellular+carcinoma%5BTitle%5D)+AND+%22Front+Oncol%22%5BJournal%5D)">Risk factors and prevention of viral hepatitis-related hepatocellular carcinoma.</a> Front Oncol. 11, 686962(2021).</li>
<li>Zou, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Economic+burden+and+quality+of+life+of+hepatocellular+carcinoma+in+greater+China%3A+A+systematic+review%5BTitle%5D)+AND+%22Front+Public+Health%22%5BJournal%5D)">Economic burden and quality of life of hepatocellular carcinoma in greater China: A systematic review.</a> Front Public Health. 10, 801981(2022).</li>
<li>Li, Y., You, Z., Tang, R., Ma, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tissue-resident+memory+t+cells+in+chronic+liver+diseases%3A+Phenotype%2C+development+and+function%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Tissue-resident memory t cells in chronic liver diseases: Phenotype, development and function.</a> Front Immunol. 13, 967055(2022).</li>
<li>Shen, K. Y., Zhu, Y., Xie, S. Z., Qin, L. X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immunosuppressive+tumor+microenvironment+and+immunotherapy+of+hepatocellular+carcinoma%3A+Current+status+and+prospectives%5BTitle%5D)+AND+%22J+Hematol+Oncol%22%5BJournal%5D)">Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: Current status and prospectives.</a> J Hematol Oncol. 17 (1), 25(2024).</li>
<li>Oura, K., Morishita, A., Tani, J., Masaki, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tumor+immune+microenvironment+and+immunosuppressive+therapy+in+hepatocellular+carcinoma%3A+A+review%5BTitle%5D)+AND+%22Int+J+Mol+Sci%22%5BJournal%5D)">Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review.</a> Int J Mol Sci. 22 (11), 5801(2021).</li>
<li>Chen, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Effect+of+infiltrating+immune+cells+in+tumor+microenvironment+on+metastasis+of+hepatocellular+carcinoma%5BTitle%5D)+AND+%22Cell+Oncol%22%5BJournal%5D)">Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma.</a> Cell Oncol. 46 (6), 1595-1604 (2023).</li>
<li>Du, Q., An, Q., Zhang, J., Liu, C., Hu, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Unravelling+immune+microenvironment+features+underlying+tumor+progression+in+the+single-cell+era%5BTitle%5D)+AND+%22Cancer+Cell+Int%22%5BJournal%5D)">Unravelling immune microenvironment features underlying tumor progression in the single-cell era.</a> Cancer Cell Int. 24 (1), 143(2024).</li>
<li>Xu, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Reshaping+the+systemic+tumor+immune+environment+%28stie%29+and+tumor+immune+microenvironment+%28time%29+to+enhance+immunotherapy+efficacy+in+solid+tumors%5BTitle%5D)+AND+%22J+Hematol+Oncol%22%5BJournal%5D)">Reshaping the systemic tumor immune environment (stie) and tumor immune microenvironment (time) to enhance immunotherapy efficacy in solid tumors.</a> J Hematol Oncol. 15 (1), 87(2022).</li>
<li>Mao, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Crosstalk+between+cancer-associated+fibroblasts+and+immune+cells+in+the+tumor+microenvironment%3A+New+findings+and+future+perspectives%5BTitle%5D)+AND+%22Mol+Cancer%22%5BJournal%5D)">Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives.</a> Mol Cancer. 20 (1), 131(2021).</li>
<li>Roederer, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Spectral+compensation+for+flow+cytometry%3A+Visualization+artifacts%2C+limitations%2C+and+caveats%5BTitle%5D)+AND+%22Cytometry%22%5BJournal%5D)">Spectral compensation for flow cytometry: Visualization artifacts, limitations, and caveats.</a> Cytometry. 45 (3), 194-205 (2001).</li>
<li>Sahaf, B., Rahman, A., Maecker, H. T., Bendall, S. C. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aSahaf%2C+B+%22Biomarkers+for+immunotherapy+of+cancer%3A+Methods+and+protocols%22">Biomarkers for immunotherapy of cancer: Methods and protocols</a>. , Springer. New York, New York, NY. (2020).</li>
<li>Turaç, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Combined+flow+cytometric+analysis+of+surface+and+intracellular+antigens+reveals+surface+molecule+markers+of+human+neuropoiesis%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Combined flow cytometric analysis of surface and intracellular antigens reveals surface molecule markers of human neuropoiesis.</a> PLoS One. 8 (6), e68519(2013).</li>
<li>Wu, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Redefining+tumor-associated+macrophage+subpopulations+and+functions+in+the+tumor+microenvironment%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment.</a> Front Immunol. 11, 1731(2020).</li>
<li>Elaldi, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High+dimensional+imaging+mass+cytometry+panel+to+visualize+the+tumor+immune+microenvironment+contexture%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">High dimensional imaging mass cytometry panel to visualize the tumor immune microenvironment contexture.</a> Front Immunol. 12, 666233(2021).</li>
<li>Gadalla, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Validation+of+cytof+against+flow+cytometry+for+immunological+studies+and+monitoring+of+human+cancer+clinical+trials%5BTitle%5D)+AND+%22Front+Oncol%22%5BJournal%5D)">Validation of cytof against flow cytometry for immunological studies and monitoring of human cancer clinical trials.</a> Front Oncol. 9, 415(2019).</li>
<li>Ijsselsteijn, M. E., Van Der Breggen, R., Farina Sarasqueta, A., Koning, F., De Miranda, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+40-marker+panel+for+high+dimensional+characterization+of+cancer+immune+microenvironments+by+imaging+mass+cytometry%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">A 40-marker panel for high dimensional characterization of cancer immune microenvironments by imaging mass cytometry.</a> Front Immunol. 10, 2534(2019).</li>
<li>Zhang, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mass+cytometry-based+peripheral+blood+analysis+as+a+novel+tool+for+early+detection+of+solid+tumours%3A+A+multicentre+study%5BTitle%5D)+AND+%22Gut%22%5BJournal%5D)">Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: A multicentre study.</a> Gut. 72 (5), 996-1006 (2023).</li>
<li>Zheng, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Trajectory+and+functional+analysis+of+pd-1%28high%29+cd4%28%2B%29cd8%28%2B%29+t+cells+in+hepatocellular+carcinoma+by+single-cell+cytometry+and+transcriptome+sequencing%5BTitle%5D)+AND+%22Adv+Sci%22%5BJournal%5D)">Trajectory and functional analysis of pd-1(high) cd4(+)cd8(+) t cells in hepatocellular carcinoma by single-cell cytometry and transcriptome sequencing.</a> Adv Sci. 7 (13), 2000224(2020).</li>
<li>Song, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Protocol+for+isolating+single+cells+from+human+pancreatic+cancer+tissues+and+analyzing+major+immune+cell+populations+using+flow+cytometry%5BTitle%5D)+AND+%22STAR+Protoc%22%5BJournal%5D)">Protocol for isolating single cells from human pancreatic cancer tissues and analyzing major immune cell populations using flow cytometry.</a> STAR Protoc. 4 (4), 102679(2023).</li>
<li>Simoni, Y., Chng, M. H. Y., Li, S., Fehlings, M., Newell, E. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mass+cytometry%3A+A+powerful+tool+for+dissecting+the+immune+landscape%5BTitle%5D)+AND+%22Curr+Opin+Immunol%22%5BJournal%5D)">Mass cytometry: A powerful tool for dissecting the immune landscape.</a> Curr Opin Immunol. 51, 187-196 (2018).</li>
<li>Comi, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Coexpression+of+cd163+and+cd141+identifies+human+circulating+il-10-producing+dendritic+cells+%28dc-10%29%5BTitle%5D)+AND+%22Cell+Mol+Immunol%22%5BJournal%5D)">Coexpression of cd163 and cd141 identifies human circulating il-10-producing dendritic cells (dc-10).</a> Cell Mol Immunol. 17 (1), 95-107 (2020).</li>
<li>Fan, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High-dimensional+single-cell+analysis+delineates+peripheral+immune+signature+of+coronary+atherosclerosis+in+human+blood%5BTitle%5D)+AND+%22Theranostics%22%5BJournal%5D)">High-dimensional single-cell analysis delineates peripheral immune signature of coronary atherosclerosis in human blood.</a> Theranostics. 12 (15), 6809-6825 (2022).</li>
<li>Sheng, J., et al. Human endogenous retrovirus activation contributes to biliary atresia pathogenesis through re-education of resident macrophages. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aSheng%2C+J+%22Biorxiv%22">Biorxiv</a>. , (2022).</li>
<li>Terekhova, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-cell+atlas+of+healthy+human+blood+unveils+age-related+loss+of+nkg2c%28%2B%29gzmb%28-%29cd8%28%2B%29+memory+t+cells+and+accumulation+of+type+2+memory+t+cells%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Single-cell atlas of healthy human blood unveils age-related loss of nkg2c(+)gzmb(-)cd8(+) memory t cells and accumulation of type 2 memory t cells.</a> Immunity. 56 (12), 2836-2854.e9 (2023).</li>
<li>Sathaliyawala, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Distribution+and+compartmentalization+of+human+circulating+and+tissue-resident+memory+t+cell+subsets%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Distribution and compartmentalization of human circulating and tissue-resident memory t cell subsets.</a> Immunity. 38 (1), 187-197 (2013).</li>
<li>Lee, S., Vu, H. M., Lee, J. H., Lim, H., Kim, M. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Advances+in+mass+spectrometry-based+single+cell+analysis%5BTitle%5D)+AND+%22Biology%22%5BJournal%5D)">Advances in mass spectrometry-based single cell analysis.</a> Biology. 12 (3), 395(2023).</li>
<li>Iyer, A., Hamers, A. A. J., Pillai, A. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cytof+for+the+masses%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Cytof for the masses.</a> Front Immunol. 13, 815828(2022).</li>
<li>Yuan, X., Wang, J., Huang, Y., Shangguan, D., Zhang, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-cell+profiling+to+explore+immunological+heterogeneity+of+tumor+microenvironment+in+breast+cancer%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Single-cell profiling to explore immunological heterogeneity of tumor microenvironment in breast cancer.</a> Front Immunol. 12, 643692(2021).</li>
<li>Serban, G. M., Mănescu, I. B., Manu, D. R., Dobreanu, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Optimization+of+a+density+gradient+centrifugation+protocol+for+isolation+of+peripheral+blood+mononuclear+cells%5BTitle%5D)+AND+%22Acta+Marisiensis+-+Seria+Medica%22%5BJournal%5D)">Optimization of a density gradient centrifugation protocol for isolation of peripheral blood mononuclear cells.</a> Acta Marisiensis - Seria Medica. 64 (2), 83-90 (2018).</li>
<li>Shcherbakova, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Factors+affecting+cell+viability+during+the+enzymatic+dissociation+of+human+endocrine+tumor+tissues%5BTitle%5D)+AND+%22Biology+%28Basel%29%22%5BJournal%5D)">Factors affecting cell viability during the enzymatic dissociation of human endocrine tumor tissues.</a> Biology (Basel). 13 (9), 665(2024).</li>
<li>Devine, R. D., Alkhalaileh, H. S., Lyberger, J. M., Behbehani, G. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Alternative+methods+of+viability+determination+in+single+cell+mass+cytometry%5BTitle%5D)+AND+%22Cytometry+A%22%5BJournal%5D)">Alternative methods of viability determination in single cell mass cytometry.</a> Cytometry A. 99 (10), 1042-1053 (2021).</li>
<li>Gonzalez, V. D., Huang, Y. W., Fantl, W. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mass+cytometry+for+the+characterization+of+individual+cell+types+in+ovarian+solid+tumors%5BTitle%5D)+AND+%22Methods+Mol+Biol%22%5BJournal%5D)">Mass cytometry for the characterization of individual cell types in ovarian solid tumors.</a> Methods Mol Biol. 2424, 59-94 (2022).</li>
<li>Zabransky, D. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Profiling+of+syngeneic+mouse+hcc+tumor+models+as+a+framework+to+understand+anti-pd-1+sensitive+tumor+microenvironments%5BTitle%5D)+AND+%22Hepatology%22%5BJournal%5D)">Profiling of syngeneic mouse hcc tumor models as a framework to understand anti-pd-1 sensitive tumor microenvironments.</a> Hepatology. 77 (5), 1566-1579 (2023).</li>
<li>Levine, L. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-cell+analysis+by+mass+cytometry+reveals+metabolic+states+of+early-activated+cd8%28%2B%29+t+cells+during+the+primary+immune+response%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Single-cell analysis by mass cytometry reveals metabolic states of early-activated cd8(+) t cells during the primary immune response.</a> Immunity. 54 (4), 829-844.e5 (2021).</li>
<li>Lv, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immunotherapy%3A+Reshape+the+tumor+immune+microenvironment%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Immunotherapy: Reshape the tumor immune microenvironment.</a> Front Immunol. 13, 844142(2022).</li>
<li>Zhou, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Deciphering+the+tumor+immune+microenvironment+from+a+multidimensional+omics+perspective%3A+Insight+into+next-generation+car-t+cell+immunotherapy+and+beyond%5BTitle%5D)+AND+%22Mol+Cancer%22%5BJournal%5D)">Deciphering the tumor immune microenvironment from a multidimensional omics perspective: Insight into next-generation car-t cell immunotherapy and beyond.</a> Mol Cancer. 23 (1), 131(2024).</li>
<li>Hsieh, W. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Spatial+multi-omics+analyses+of+the+tumor+immune+microenvironment%5BTitle%5D)+AND+%22J+Biomed+Sci%22%5BJournal%5D)">Spatial multi-omics analyses of the tumor immune microenvironment.</a> J Biomed Sci. 29 (1), 96(2022).</li>
<li>Wang, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Gdf15+induces+immunosuppression+via+cd48+on+regulatory+t+cells+in+hepatocellular+carcinoma%5BTitle%5D)+AND+%22J+Immunother+Cancer%22%5BJournal%5D)">Gdf15 induces immunosuppression via cd48 on regulatory t cells in hepatocellular carcinoma.</a> J Immunother Cancer. 9 (9), e002787(2021).</li>
<li>Krams, S. M., Schaffert, S., Lau, A. H., Martinez, O. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Applying+mass+cytometry+to+the+analysis+of+lymphoid+populations+in+transplantation%5BTitle%5D)+AND+%22Am+J+Transplant%22%5BJournal%5D)">Applying mass cytometry to the analysis of lymphoid populations in transplantation.</a> Am J Transplant. 17 (8), 1992-1999 (2017).</li>
</ol>

<table><tbody><tr><td>1&times;PBS</td><td>HyClone</td><td>SH30256.01</td><td></td></tr><tr><td>10&times;PBS</td><td>HyClone</td><td>SH30256.01</td><td></td></tr><tr><td>100 mm&times;20 mm tissue-culture-treated culture dish</td><td>Corning</td><td>430167</td><td></td></tr><tr><td>1000 mL pipette tips</td><td>Rainin</td><td>30389218</td><td></td></tr><tr><td>15 mL centrifuge tube</td><td>NEST</td><td>601052</td><td></td></tr><tr><td>200 mL pipette tips</td><td>Rainin</td><td>30389241</td><td></td></tr><tr><td>40 mm nylon cell strainer/70-mm nylon cell strainer</td><td>Falcon</td><td>352340</td><td></td></tr><tr><td>50 mL centrifuge tube</td><td>NEST</td><td>602052</td><td></td></tr><tr><td>70 &mu;m syringe fifilter</td><td>Sangon Biotech</td><td>F613462-9001</td><td></td></tr><tr><td>Anti-Human CCR2 Antibody (clone: K036C2)</td><td>BioLegend</td><td>357224</td><td></td></tr><tr><td>Anti-Human CCR3 Antibody (clone: 5E8)</td><td>BioLegend</td><td>310724</td><td></td></tr><tr><td>Anti-Human CCR7 Antibody (clone: G043H7)</td><td>BioLegend</td><td>353240</td><td></td></tr><tr><td>Anti-Human CD103 Antibody (clone: Ber-ACT8)</td><td>BioLegend</td><td>350202</td><td></td></tr><tr><td>Anti-Human CD115 Antibody (clone: 9-4D2-1E4)</td><td>BioLegend</td><td>347314</td><td></td></tr><tr><td>Anti-Human CD117 Antibody (clone: 104D2)</td><td>BioLegend</td><td>313201</td><td></td></tr><tr><td>Anti-human CD11b Antibody (clone: 1CRF44)&nbsp;</td><td>BD</td><td>562721</td><td></td></tr><tr><td>Anti-human CD11c Antibody (clone: B-ly6)&nbsp;</td><td>BD</td><td>563026</td><td></td></tr><tr><td>Anti-Human CD123 Antibody (clone: 6H6)</td><td>BioLegend</td><td>306002</td><td></td></tr><tr><td>Anti-Human CD127 Antibody (clone: A019D5)</td><td>BioLegend</td><td>351337</td><td></td></tr><tr><td>Anti-Human CD13 Antibody (clone: WM19)</td><td>BioLegend</td><td>301701</td><td></td></tr><tr><td>Anti-Human CD138 Antibody (clone: MI15)</td><td>BioLegend</td><td>356535</td><td></td></tr><tr><td>Anti-human CD14 Antibody (clone: HCD14)</td><td>BioLegend</td><td>325604</td><td></td></tr><tr><td>Anti-Human CD141 Antibody (clone: M80)</td><td>BioLegend</td><td>344102</td><td></td></tr><tr><td>Anti-Human CD15 Antibody (clone: QA19A61)</td><td>BioLegend</td><td>376302</td><td></td></tr><tr><td>Anti-human CD16 Antibody (clone: B7311)&nbsp;</td><td>BD</td><td>561313</td><td></td></tr><tr><td>Anti-Human CD161 Antibody (clone: HP-3G10)</td><td>BioLegend</td><td>339902</td><td></td></tr><tr><td>Anti-Human CD163 Antibody (clone: GHI/61)</td><td>BioLegend</td><td>333603</td><td></td></tr><tr><td>Anti-Human CD169 Antibody (clone: 7-239)</td><td>BioLegend</td><td>346002</td><td></td></tr><tr><td>Anti-human CD19 Antibody (clone: HIB19)</td><td>BioLegend</td><td>302226</td><td></td></tr><tr><td>Anti-Human CD1c Antibody (clone: L161)</td><td>BioLegend</td><td>331501</td><td></td></tr><tr><td>Anti-Human CD20 Antibody (clone: 2H7)</td><td>BioLegend</td><td>302301</td><td></td></tr><tr><td>Anti-Human CD206 Antibody (clone: 15-2)</td><td>BioLegend</td><td>321151</td><td></td></tr><tr><td>Anti-Human CD24 Antibody (clone: ML5)</td><td>BioLegend</td><td>311129</td><td></td></tr><tr><td>Anti-Human CD25 Antibody (clone: BC96)</td><td>BioLegend</td><td>302624</td><td></td></tr><tr><td>Anti-human CD3 Antibody (clone: UCHT1)&nbsp;</td><td>BD</td><td>555916</td><td></td></tr><tr><td>Anti-Human CD31 Antibody (clone: W18200D)</td><td>BioLegend</td><td>375902</td><td></td></tr><tr><td>Anti-Human CD32 Antibody (clone: FUN-2)</td><td>BioLegend</td><td>303232</td><td></td></tr><tr><td>Anti-Human CD326 Antibody (clone: CO17-1A)</td><td>BioLegend</td><td>369812</td><td></td></tr><tr><td>Anti-Human CD33 Antibody (clone: WM53)</td><td>BioLegend</td><td>303402</td><td></td></tr><tr><td>Anti-human CD4 Antibody (clone: L200)&nbsp;</td><td>BD</td><td>563094</td><td></td></tr><tr><td>Anti-Human CD45 Antibody (clone: HI30)&nbsp;</td><td>BD</td><td>563716</td><td></td></tr><tr><td>Anti-Human CD45RO Antibody (clone: UCHL1)</td><td>BioLegend</td><td>304220</td><td></td></tr><tr><td>Anti-human CD56 Antibody (clone: 5.1H11)</td><td>BioLegend</td><td>362510</td><td></td></tr><tr><td>Anti-Human CD64 Antibody (clone: S18012C)</td><td>BioLegend</td><td>399502</td><td></td></tr><tr><td>Anti-Human CD66b Antibody (clone: 6/40c)</td><td>BioLegend</td><td>392917</td><td></td></tr><tr><td>Anti-human CD68 Antibody (clone: Y1/82A)</td><td>BioLegend</td><td>333808</td><td></td></tr><tr><td>Anti-Human CD69 Antibody (clone: FN50)</td><td>BioLegend</td><td>310902</td><td></td></tr><tr><td>Anti-Human CD7 Antibody (clone: 4H9/CD7)</td><td>BioLegend</td><td>395602</td><td></td></tr><tr><td>Anti-human CD8 Antibody (clone: RPA-T8)&nbsp;</td><td>BD</td><td>557750</td><td></td></tr><tr><td>Anti-Human CD80 Antibody (clone: W17149D)</td><td>BioLegend</td><td>375402</td><td></td></tr><tr><td>Anti-Human CD86 Antibody (clone: BU63)</td><td>BioLegend</td><td>374202</td><td></td></tr><tr><td>Anti-Human FOXP3 Antibody (clone: 206D)</td><td>BioLegend</td><td>320101</td><td></td></tr><tr><td>Anti-Human HLA_ABC Antibody (clone: W6/32)</td><td>BioLegend</td><td>311426</td><td></td></tr><tr><td>Anti-human HLA-DR Antibody (clone: L243)</td><td>BioLegend</td><td>307650</td><td></td></tr><tr><td>Anti-Human IgD Antibody (clone: IA6-2)</td><td>BioLegend</td><td>348211</td><td></td></tr><tr><td>Anti-Human Ki67 Antibody (clone: Ki-67)</td><td>BioLegend</td><td>350501</td><td></td></tr><tr><td>Anti-Human PD_L2 Antibody (clone: MH22B2)</td><td>BD</td><td>567783</td><td></td></tr><tr><td>Anti-Human PD1 Antibody (clone: EH12.2H7)</td><td>BioLegend</td><td>329951</td><td></td></tr><tr><td>Anti-Human PDL1 Antibody (clone: MIH2)</td><td>BioLegend</td><td>393602</td><td></td></tr><tr><td>Anti-human TCR-&gamma;&delta; Antibody (clone: B1)&nbsp;</td><td>BD</td><td>74

肝細胞癌における全身および局所免疫応答のマスサイトメトリー解析

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common and deadliest forms of liver cancer worldwide. Despite advances in treatment, the prognosis for ...

mass-cytometry-analysis-systemic-local-immune-responses

Research

JoVE Journal

Biology

生物学

ここで分離し、確立された皮下腫瘍における腫瘍免疫と免疫のない微小環境のコンポーネントを豊かにする方法をについて説明します。この手法は、腫瘍免疫浸潤と非免疫腫瘍腫瘍免疫微小環境の包括的な評価を可能にすることができます独立した分析のためことができます。...

濃縮と確立された皮下マウス腫瘍における腫瘍免疫と免疫のない微小のキャラクタリゼーション

免疫表現型と機能 (細胞内サイトカイン誘導)...

イムノフェノ タイプと大量のフローサイトメトリーによる末梢血中のサイトカイン産生の単一細胞解析

ここでは、肝細胞癌(HCC)の典型的な免疫特徴を要約した肝癌の臨床的に関連するマウスモデルの開発について述べた。...

肝炎症と線維症の設定に起因する肝細胞癌の腫瘍性肝細胞誘発性オルコトピックマウスモデル

がん細胞によるナチュラルキラー(NK)細胞介在の根絶の回避は、がんの開始と進行に重要です。ここでは、肝腫瘍細胞に対するNK細胞媒介性細胞毒性を評価するための非放射活性ベースの2つのプロトコルを紹介する。さらに、NK細胞の移動を分析するための第3のプロトコルが提示されます。...

肝腫瘍細胞の文脈における自然キラー細胞媒介性細胞毒性と遊性の測定

ここでは、ホルマリン固定パラフィン埋め込み腫瘍組織切片における免疫細胞の可視化、定量、およびマッピングのための簡単でアクセス可能な戦略について述べている。この方法論は、既存のイメージングおよびデジタル解析技術と、イメージングアッセイの多重化能力と多パラメータ分析を拡大することを目的と組み合わせたものです。...

腫瘍微小環境における免疫細胞集団の可視化、定量化、およびマッピング

関連するヒト疾患を忠実に再現する包括的な インビトロ モデルが欠けている。現在の研究は、ヒト肝細胞癌における腫瘍間質相互作用を研究するための信頼性の高い インビトロ...

肝細胞癌における腫瘍間質相互作用を調べる三次元スフェロイドモデル

このプロトコルは、免疫腫瘍学研究のためのヒト免疫系(HIS)マウスの生成について概説しています。このモデルに移植されたヒト腫瘍に対するヒト免疫療法を試験するためのこのモデルの使用における指示および考慮事項は、腫瘍に対するヒト免疫系の応答を特徴付けることに重点を置いたものとして提示されている。...

ヒト腫瘍を有するヒト化マウスモデルにおける癌免疫療法の試験

ここでは、がん免疫サイクルを構成するステップをモニターし、特性評価するための、シンプルで高速、かつ信頼性の高いマルチパラメトリックフローサイトメトリーおよびTumor-on-a-chip支援プロトコルについて詳しく説明します。実際、がんと免疫細胞の相互作用を完全に理解することで、腫瘍を出し抜き、臨床ケアを導くための重要な洞察が得られます。...

がん免疫サイクルを再現するためのin vitro共培養システム

切除後の肝細胞がんの内縁および腫瘍周囲領域に肥満細胞が存在することは、予後が良好である。この研究は、QuPath画像解析ソフトウェアが、デジタルパソロジーにおける再現性、一貫性、精度のニーズを満たす可能性のある有望なプラットフォームであることを支持しています。...

肝細胞癌の微小環境における肥満細胞は予後良好をもたらす:QuPath画像解析ソフトウェアを使用したレトロスペクティブ研究 

このビデオでは、解剖や胎児の胸腺の除去だけでなく、2 - dGuo処理胸腺のex...

2 - dGuo処理した胸腺器官培養の準備

学ぶマスサイトメトリーによる肝細胞癌における単一細胞レベルの免疫プロファイリング手法。14種類の免疫細胞サブセットを同定し、腫瘍免疫相互作用の理解と個別化治療への応用を可能にする。

肝細胞癌における全身および局所免疫応答のマスサイトメトリー解析

さらに動画を探す